One of the most promising nonopioid therapeutics to emerge in the past two decades was the monoclonal antibody-sequestering nerve growth factor (NGF) tanezumab, which showed efficacy in clinical trials for osteoarthritis (1), low back pain (2), neuropathic pain (3), and cancer pain (4). The gene discussed is NGF; the disease is cancer.